Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating giant cell arteritis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6299
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- AbbVie
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK)
- Vasculitis UK
- Professional groups
- British Society for Rheumatology
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Fresenius Kabi (tocilizumab) – confidentiality agreement not signed, not participating
- Roche (tocilizumab) – confidentiality agreement signed, participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 February 2026 | Note added to the project documents |
| 14 January 2026 - 04 February 2026 | Draft guidance |
| 10 December 2025 | Committee meeting: 1 |
| 10 December 2025 | Declaration of interests |
| 01 October 2025 | Note - Note added to the project documents |
| 23 May 2025 | Note - Note added to the project documents |
| 14 March 2025 | Invitation to participate |
| 23 January 2025 - 20 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6299 |
| 23 January 2025 | In progress. Scoping commencing |
| 06 December 2024 | Note - Note added to the project documents |
| 13 May 2024 | Note - Note added to the project documents |
| 28 April 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual